Harrow Inc
HROW
View Detailed Chart
41.300USD
+0.280+0.68%
Close 11/26, 16:00（ET）Quotes delayed by 15 min
1.53BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+0.68%
5 Days
+9.67%
1 Month
+8.00%
6 Months
+56.86%
Year to Date
+23.10%
1 Year
-2.75%
View Detailed Chart
TradingKey Stock Score of Harrow Inc
Currency: USD Updated: 2025-11-26Key Insights
The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Harrow Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
8
analysts
Buy
Current Rating
70.714
Target Price
+71.22%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Harrow Inc Highlights
StrengthsRisks
Harrow, Inc. is an eyecare pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the United States market. It provides a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 125.31% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 199.61M.
Undervalued
The company’s latest PE is -316.62, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 21.75M shares, decreasing 13.06% quarter-over-quarter.
Held by Private Capital
Star Investor Private Capital holds 1.86M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.25.
Harrow Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Harrow Inc Info
Harrow, Inc. is an eyecare pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the United States market. It provides a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.
Ticker SymbolHROW
CompanyHarrow Inc
CEOMr. John P. Saharek
Websitehttps://www.harrow.com/
FAQs
What is the current price of Harrow Inc (HROW)?
The current price of Harrow Inc (HROW) is 41.300.
What is the symbol of Harrow Inc?
The ticker symbol of Harrow Inc is HROW.
What is the 52-week high of Harrow Inc?
The 52-week high of Harrow Inc is 50.720.
What is the 52-week low of Harrow Inc?
The 52-week low of Harrow Inc is 20.850.
What is the market capitalization of Harrow Inc?
The market capitalization of Harrow Inc is 1.53B.
What is the net income of Harrow Inc?
The net income of Harrow Inc is -17.48M.
Is Harrow Inc (HROW) currently rated as Buy, Hold, or Sell?
According to analysts, Harrow Inc (HROW) has an overall rating of Buy, with a price target of 70.714.
What is the Earnings Per Share (EPS TTM) of Harrow Inc (HROW)?
The Earnings Per Share (EPS TTM) of Harrow Inc (HROW) is -0.130.
Related Instruments
-0.49%
+0.40%
-1.81%
+0.09%
-0.97%
+0.14%
+1.01%
+3.47%
+0.31%
-0.08%
-0.50%
+0.55%
-0.62%
+0.41%
+0.98%
-0.61%
-0.34%
0.00%
+3.56%
-0.17%
